Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review

Peerlings, Jurgen; Voorde, Lien Van De; Mitea, Cristina; Larue, Ruben T. H. M.; Yaromina, Ala; Sandeleanu, Sebastian; Spiegelberg, Linda; Dubois, Ludwig; Mottaghy, Felix M.

doi:10.1016/j.ymeth.2017.07.002

Cited by 43 publications

(42 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Direct imaging of oxygen using 19 F MRI or blood oxygen level dependent MRI (BOLD MRI) is also possible, however with their own limitations. In the case of 19 F MRI, local injections into the tumor are necessary while in BOLD MRI the signal can be influenced by factors other than hypoxia, resulting in low specificity [93] . A promising MRI technique proposed by O’Connor and colleagues is oxygen enhanced MRI (OE-MRI), which is less invasive and potentially more specific [94] , [95] .…”

Section: Hypoxia Selection By Biomarkersmentioning

confidence: 99%

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Spiegelberg

Houben

Niemans

et al. 2019

Clinical and Translational Radiation Oncology

Self Cite

134

View full text Add to dashboard Cite

HighlightsHypoxia-activated prodrugs have yielded promising results up to phase II trials.Implementation of hypoxia-activated prodrugs in the clinic has not been successful.Phase III clinical trials lack patient stratification based on tumor hypoxia status.Stratification will decrease the number of patients needed and increase success.Improvements in hypoxia-activated prodrug design can also increase success rates.

show abstract

Section: Hypoxia Selection By Biomarkersmentioning

confidence: 99%

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Spiegelberg

Houben

Niemans

et al. 2019

Clinical and Translational Radiation Oncology

Self Cite

134

View full text Add to dashboard Cite

show abstract

“…CA9 is not detected in most normal tissues, but its expression in various cancers indicates hypoxic tumors and poor treatment response 57 . Glut1 is one of hypoxia biomarkers and associated with poor prognosis in various cancers [58][59][60] . Glut1 is HIF-1 target genes and enhanced in cells exposed to intermittent hypoxia in colon cancer 61 .…”

Section: Discussionmentioning

confidence: 99%

Intermittent hypoxia exacerbates tumor progression in a mouse model of lung cancer

Kang

Kwon

Kim

et al. 2020

Sci Rep

View full text Add to dashboard Cite

the purpose of this study was to evaluate whether obstructive sleep apnea (oSA)-related chronic intermittent hypoxia (CIH) influences lung cancer progression and to elucidate the associated mechanisms in a mouse model of lung cancer. C57/BL6 mice in a CIH group were exposed to intermittent hypoxia for two weeks after tumor induction and compared with control mice (room air). Hypoxia inducible factor 1α (HIF-1α), vascular endothelial growth factor (VeGf) and metastasis-related matrix metalloproteinases (MMp) were measured. the expression levels of several hypoxia-related pathway proteins including HIF-1α, Wnt/ß-catenin, the nuclear factor erythroid 2-related factor 2 (Nrf2) and mammalian target of rapamycin-eRK were measured by western blot. the number (p < 0.01) and volume (p < 0.05) of tumors were increased in the CIH group. The activity of MMP-2 was enhanced after CIH treatment. The level of VEGF was increased significantly in the CIH group (p < 0.05). ß-catenin and Nrf2 were translocated to the nucleus and the levels of downstream effectors of Wnt/ß-catenin signaling increased after iH exposure. ciH enhanced proliferative and migratory properties of tumors in a mouse model of lung cancer. ß-catenin and Nrf2 appeared to be crucial mediators of tumor growth. Obstructive sleep apnea (OSA) is characterized by recurrent occlusion of the upper airway during sleep leading to chronic intermittent hypoxia (CIH). OSA is a highly prevalent sleep disorder affecting at least 3% to 7% of the adult population 1. OSA has been shown to be associated with morbidities including metabolic syndrome, systemic hypertension, pulmonary vascular disease, ischemic heart disease and congestive heart failure 2. In addition, OSA-related CIH has been suggested to affect tumor development and progression 3. OSA has been implicated in the increasing incidence of certain types of solid malignancies. In a Spanish cohort, increased overnight hypoxia as a surrogate of OSA severity was associated with increased cancer incidence in selected populations 4-6. Also, OSA was associated with increased cancer mortality in a community-based sample 7. The association between OSA and lung cancer has been evaluated. OSA-related CIH induced resistance to apoptosis and increased metastasis in lung cancer cells, in a manner related to hypoxia inducible factor 1α (HIF-1α) 8. The role of immune cells has been suggested as a potential mechanism linking OSA and cancer. Almendros et al. demonstrated that CIH induced changes in host immune responses are related to adverse cancer outcomes. CIH increases the mobilization of tumor-associated macrophages (TAMs) into tumors, and induces macrophages to transform from an anti-tumor phenotype (M1) to a tumor-promoting phenotype (M2) 9. Cyclooxygenase-2 inhibited IH-induced M2 polarization of TAMs and prevented IH-induced adverse tumor outcomes in a mouse model of sleep apnea 10. OSA-related CIH altered CD8 + T-cells in combination with changes in the tumor microenvironment that enhanced malignant tumor properties 11. Studies...

show abstract

“…Hypoxia is associated with cancer invasion, angiogenesis, distant metastasis and epithelial–mesenchymal transition (EMT) . Many studies have shown that hypoxia‐inducible factor 1α (HIF‐1α) is correlated with cancer progression and metastasis . Many studies have suggested that propofol regulates cancer development via the HIF‐1α pathway.…”

Section: Genetic Signaling Pathwaysmentioning

confidence: 99%

“…44 Many studies have shown that hypoxia-inducible factor 1 (HIF-1 ) is correlated with cancer progression and metastasis. 45 Many studies have suggested that propofol regulates cancer development via the HIF-1 pathway. Takabuchi et al proved that propofol inhibited HIF-1 protein synthesis which was dependent on the cellular oxygen tension.…”

Section: Propofol and The Hypoxia Pathwaymentioning

confidence: 99%

The mechanism of propofol in cancer development: An updated review

Gao

Guo

et al. 2020

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Cancer is a key cause of death worldwide. Despite the development of radiotherapy, chemotherapy and even immunotherapy, surgery remains the standard treatment for cancer patients. Recently, many studies have shown that propofol, a commonly used anesthetic drug, can affect the prognosis of cancer. In this review, we provide an overview of the molecular mechanisms of propofol in the development of cancer. Propofol not only affects epigenetic pathways, such as those involving miRNA, lncRNA and histone acetylation, but also modulates genetic signaling pathways, including the hypoxia, NF‐κB, MAPK, SLUG and Nrf2 pathways. In addition, propofol influences the immune function of patients and impacts the degree of immunosuppression. Furthermore, we briefly summarize the clinical trials on the effect of propofol in cancer development. Ultimately, further studies distinguishing the types of tumors in clinical trials are needed to clarify the correlation between propofol and cancer.

show abstract

Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review

Cited by 43 publications

References 74 publications

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Intermittent hypoxia exacerbates tumor progression in a mouse model of lung cancer

The mechanism of propofol in cancer development: An updated review

Contact Info

Product

Resources

About